When Kay Dickersin was diagnosed with breast cancer in 1986, the support group available to her in Baltimore focused largely on how to get the makeup and wig to look right.
In an interview with the Cancer History Project, Kay Dickersin, one of the early leaders of the grassroots breast cancer patient advocacy movement, recounted the beginnings of the National Breast Cancer Coalition.
A regimen including oral paclitaxel plus Athenex (encequidar) in combination with a PD-1 inhibitor and carboplatin showed positive results in triple-negative, high-risk, early-stage breast cancer. The oral paclitaxel, relative to intravenous paclitaxel, was associated with less neuropathy and was not associated with an increase in febrile neutropenia.
An Indiana University School of Medicine study produced a potential biomarker for chemotherapy-induced cardiotoxicity in breast cancer patients. The researchers also identified a drug that may work to minimize cardiotoxicity.
Monica Bertagnolli, the 16th director of the National Cancer Institute, announced that she will be undergoing treatment for early-stage breast cancer.
Results from the RIGHT Choice phase II trial showed that Kisqali (ribociclib) plus endocrine therapy demonstrated a nearly one-year PFS benefit for patients with aggressive breast cancer.
Detailed results from the CAPItello-291 phase III trial showed AstraZeneca’s capivasertib in combination with Faslodex (fulvestrant) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival versus placebo plus Faslodex in patients with hormone receptor-positive, human epidermal growth factor receptor 2-low or negative, locally advanced or metastatic breast cancer, following recurrence or progression on, or after, endocrine therapy (with or without a CDK4/6 inhibitor).
Retrospective analyses of data from the Suppression of Ovarian Function Trial trial, led by Hologic Inc. and its subsidiary, Biotheranostics Inc., showed that the Breast Cancer Index test identified which premenopausal patients with early-stage, hormone-receptor positive breast cancer benefited from the addition of ovarian function suppression to primary adjuvant endocrine therapy.
While it has long been recognized that drugs that block the cancer-promoting activity of estrogen reduce risk of developing new breast cancers, a new computer modeling study led by researchers at Georgetown Lombardi Comprehensive Cancer Center and colleagues showed that these treatments could also reduce the risk of dying from the disease in women who are at high risk.
A multicenter analysis of patients with invasive lobular carcinoma—the second most common histological subtype of invasive breast cancer in the U.S.—showed that, despite its prevalence, ILC is detected later and has worse outcomes than the predominant subtype of invasive breast cancer, known as invasive ductal carcinoma, or no special type.
